Combined use of CA 125 and Inhibin as tumor marker for detection of ovarian cancer in comparison to CA 125 or Inhibin alone
نویسندگان
چکیده
منابع مشابه
the prognosticrole of tumor marker ca-125 in b-cell
background: b-cell non-hodgkin’s lymphoma (nhl) is a common malignancy of lymphoid tissues. different types of nhl show various behaviors, prognoses, and responses to treatment. evaluation of disease activity in nhl can be helpful in managing and even increasing the patient’s survey. methods and results: in total, 121 patients (76 males and 45 females), and their age range were 18-53 years, wer...
متن کاملSerum CA 125 and ovarian cancer
of death from gynaecological cancer among women in Western countries. Epithelial ovarian cancer is responsible for 85-90% of all primary ovarian tumours. Because of the asymptomatic nature of the disease, ovarian cancer is usually not detected in the early stages and therefore many women present with advanced disease and systemic metastases. Approximately 70-80% of patients present with late st...
متن کاملLevel and evaluation of tumor marker CA-125 in ovarian cancer patients in Khyber Pakhtunkhwa, Pakistan.
BACKGROUND Due to the increase in morbidity and mortality rate, cancer has become an alarming threat to the human population worldwide. Since cancer is a progressive disorder, timely diagnosis is necessary to prevent/stop cancer from progressing to a severe stage. In Khyber Paktunkhwa, Pakistan, many tumors are diagnosed with endoscopy and biopsy; rare studies exist regarding the diagnosis and ...
متن کاملThe tumor marker CA-125 and heart failure.
D’Aloia et al4 described a significant correlation between elevated serum CA125 and advanced functional class, and other hemodynamic parameters related to severity, in 286 patients with chronic heart failure. The biomarker was also associated with a poorer short-term prognosis. Other groups have since confirmed this association in both acute5 and chronic heart failure.6.7 We recently observed t...
متن کاملHE4, CA-125, and cystic ovarian mass
To the editor: The recent publication on ‘HE4, CA-125, and cystic ovarian mass’ is very interesting [1]. Partheen et al. [1] concluded that HE4 did not outperform CA-125. Indeed, the use of two biomarkers might be expected for increased screening ability; however, the problem of the cost should be kept in mind. Incremental analysis on additional cost should be done. Based on the present report,...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International Journal of Reproduction, Contraception, Obstetrics and Gynecology
سال: 2017
ISSN: 2320-1789,2320-1770
DOI: 10.18203/2320-1770.ijrcog20175234